DHHSHIV14072b
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
For additional copies: info@GuidelineCentral.com
Copyright © 2014 All rights reserved
Disclaimer
is Guideline attempts to define principles of practice that should produce high-quality patient care. It
focuses on the needs of primary care practice, but also is applicable to providers at all levels.
is Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining
the same results. e ultimate judgment concerning the propriety of any course of conduct must be made by
the clinician aer consideration of each individual patient situation.
Neither IGC, the medical associations, nor the authors endorse any product or service associated with the
distributor of this clinical reference tool.
Source
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of
antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and
Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/
adultandadolescentgl.pdf. Accessed: 5/1/14
Rating Scheme for Recommendations
Strength of Recommendation Quality of Evidence for Recommendation
A: Strong recommendation for the
statement
I: One or more randomized trials with clinical
outcomes and/or validated laboratory
endpoints
B: Moderate recommendation for
the statement
II: One or more well-designed, nonrandomized
trials or observational cohort studies with
long-term clinical outcomes
C: Optional recommendation III: Expert opinion
Abbreviations
3TC, lamivudine; ABC, abacavir; Al+++, aluminum; ALT, alanine aminotransferase;
ART, antiretroviral therapy; ARV, antiretroviral; AST, aspartate aminotranserase; ATV/r,
ritonavir-boosted atazanavir; bid, twice daily; BMD, bone mineral density; CaCO3,
Calcium carbonate; CBC, complete blood count; CD4, CD4 T lymphocyte; cobi,
cobicistat; CrCl, creatinine clearance; CYP, cytochrome P; DRV/r, ritonavir-boosted
darunavir; DTG, dolutegravir; EFV, efavirenz; EVG, elvitegravir; FTC, emtricitabine;
GI, gastrointestinal; HBV, hepatitis B virus; HSR, hypersensitivity reaction; HBsAb,
hepatitis B surface antibody; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus;
INSTI, integrase strand transfer inhibitor; LPV/r, ritonavir-boosted lopinavir; Mg++,
magnesium; MDRD, modification of diet in renal disease (equation); MI, myocardial
infarction; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside
reverse transcriptase inhibitor; PI, protease inhibitor; PI/r, ritonavir-boosted protease
inhibitor; PPI, proton pump inhibitor; RAL, raltegravir; RPV, rilpivirine; SJS, Stevens-
Johnson syndrome; RTV, ritonavir; TDF, tenofovir; TEN, toxic epidermal necrosis;
ZDV, zidovudine
